Industry Leader in Generic Market Information Offers Newport Horizon
SHANGHAI, China, June 24 /Xinhua-PRNewswire/ -- Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, today announced at CPhI China 2008(1) the release of Newport Horizon Premium, designed specifically for professionals working in product selection, business development, competitive intelligence and API (Active Pharmaceutical Ingredient) sourcing. Their use by generic and OTC (Over the Counter) pharmaceutical companies and API manufacturers in China and worldwide will enable them to find the most appropriate product development opportunities more quickly.
This new solution offered by the Scientific business of Thomson Reuters will help provide a competitive boost to China's pharmaceutical industry which has seen substantial growth in the generic and API sectors in recent years. The number of Type II US Drug Master Files(2) (DMFs) granted by the US Food & Drug Administration, to Chinese headquartered companies has increased almost 10-fold since 1999, far exceeding the rate of growth to companies headquartered in other markets, according to Thomson Reuters' Centre for Medicines Research (CMR) International 2008 R&D Factbook ( http://www.cmr.org ).
Said Dr. David Liu, Senior Director and Head of China Regional Business Unit for the Scientific business of Thomson Reuters, ''These forecasts indicate the vast market potential of pharmaceutical enterprises in China which have a critical need for authoritative generics market information in order to gain a clear advantage over competitors. As the industry authority on the global generics market, we recognize this and developed Newport Horizon Premium to help customers improve productivity, accelerate time to market, and gain that competitive edge in the generics marketplace.''
Newport Horizon Premium combines sales, consumption, launch, patent, patent challenge, exclusivity, chemistry, prescribing and regulatory information for more than 10,000 molecules, 18,000 companies, 68 markets and 92 patent countries worldwide with unique, early API development and manufacturing intelligence. They build on the substantial success of Horizon Global, by adding patented and published routes of synthesis on thousands of molecules, with listed intermediates and reagents, sourced from Prous Science's respected Synthline database. Newport Horizon Premium also has kilogram and IU (International Units) API consumption data from IMS Health added to the data and capabilities already available. This data is now available for thousands of drugs by region and by dose form for both the current and previous year and allow customers to evaluate scale, consumption trends and prices for active ingredients, all of which can be difficult to estimate using sales data alone.
This new solution from Scientific addresses the needs of large and small players in the pharmaceuticals market and features powerful multi-criteria search functionalities. Newport Horizon Premium is aimed at helping generic, OTC and API companies in their constant struggle to build deals faster and accelerate time to market.
The Scientific business of Thomson Reuters provides information and knowledge to accelerate research, discovery and innovation. Our authoritative, accurate and timely information is essential for drug companies to discover new drugs and get them to market faster; researchers to find relevant papers and know what's newly published in their subject; and businesses to optimize their intellectual property and find competitive intelligence. We create the research platforms and services of the future that will power our customers toward business and personal success. Scientific information solutions can be found at http://scientific.thomsonreuters.com .
About Thomson Reuters
Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. For more information, go to http://thomsonreuters.com .
Notes to Editor:
(1) CPhI China 2008 is held at Shanghai New International Expo Centre from 24-26 June and is the leading exhibition on pharmaceutical ingredients and allied industries http://www.cphi-china.com
Mr. David Harding, Newport Specialist, Scientific business of Thomson Reuters, will be presenting during CPhI on 25 June 2008 at 2:30PM at E5 Exhibition Hall.
(2) US Drug Master File (DMF): A confidential document covering a
specific manufacturing facility, process or article used in the
manufacture, processing, packaging or storing of a bulk drug (API), which
is covered in an ANDA. DMFs are never approved or disapproved by the FDA,
but are kept on file and only reviewed when a manufacturer files an ANDA
(Abbreviated New Drug Application) or an NDA referencing the DMF.
For more information, please contact:
Manager, PR & Communications
|SOURCE Thomson Reuters|
Copyright©2008 PR Newswire.
All rights reserved